Retatrutide 10mg

Retatrutide (LY3437943) is a synthetic 39-amino-acid peptide engineered as a balanced triple agonist of the GLP-1, GIP, and glucagon receptors. It represents the next generation of incretin-based research compounds, adding glucagon receptor activation to the dual agonism architecture seen in earlier molecules. Research labs use retatrutide to study energy expenditure, hepatic glucose output, and lipid oxidation in controlled metabolic models. Its non-natural residues (Aib at positions 2 and 20, alpha-methyl-L-leucine at position 13) and C-terminal amidation confer proteolytic stability, while the C20 fatty-acid acylation enables albumin binding for extended half-life. Our retatrutide is >99.6% pure, validated by HPLC-UV and ESI-MS, and ships in a 10 mg lyophilized vial with full analytical documentation. FAQs What is retatrutide? Retatrutide is a synthetic triple agonist peptide targeting GLP-1, GIP, and glucagon receptors, studied in laboratory models of metabolic regulation and energy homeostasis. Where can I buy retatrutide for research? You can buy research-grade retatrutide from Haelo Labs. Our 10 mg vials are third-party tested with HPLC and mass spectrometry verification. How does retatrutide compare to tirzepatide? Retatrutide adds glucagon receptor activation to the GLP-1/GIP dual agonism of tirzepatide. Researchers compare both to study the metabolic effects of triple vs. dual receptor targeting.